Bayer Faces Billions in Payouts

Jury orders Bayer to pay $100 million over PCBs in Washington school
A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals known as PCBs at a Seattle-area school, but found the company was not liable for injuries alleged by 11 others.
Bayer Says It Was Told by Jury to Pay $100 Million Over Toxic Chemicals
Bayer AG was told by a jury to pay $100 million to four people at a Seattle-area school who said their exposure at the facility to toxic chemicals made by the company’s Monsanto unit caused brain damage and other injuries.
Bayer faces billions in payouts for half century-old toxic mess
Bayer is facing billions of dollars in exposure from a growing number of lawsuits over PCB products. Read more at straitstimes.com.
Bayer must pay $100 million in latest trial over PCBs in Washington school, jury finds
A Washington state jury on Tuesday said Bayer must pay $100 million to four people who say they were sickened by exposure to toxic chemicals known as PCBs made by the company's predecessor Monsanto that were used in light fixtures at a Seattle-area school,
Bayer Hit with $100 Million Verdict Over Toxic PCB Exposure
Bayer AG faces a $100 million jury verdict over PCB exposure at a Seattle school amid ongoing legal challenges related to toxic chemicals.
Bayer Hit With $100 Million Verdict Over School’s Toxic PCBs (2)
Bayer AG was told by a jury to pay $100 million to four people at a Seattle-area school who said their exposure at the facility to toxic chemicals made by the company’s Monsanto unit caused brain damage and other injuries.
Bayer | Morning Blend
As we usher in 2025, it’s the perfect time to prioritize health and wellness. Registered Dietitian and Nutritionist Kelly ...
Bayer’s Head of Pharma Oelrich Expects Business to Return to Growth in 2027
Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...
Cutting Middle Management: Bayer's Costly Experiment One Year Later
In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.
Bayer plant doch keine Pharma-Großdeals, Fokus Schuldenabbau
Mit Blick auf die Neuausrichtung der Medikamentenpipeline von Bayer hatte Pharma-Chef Stefan Oelrich im letzten Januar ...
Bayer says menopause drug succeeds in breast cancer study
The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...
Foreign Policy4h
Bayer Phase 1 Menopause Issue Brief
Despite there currently being over 1 billion menopausal or postmenopausal women worldwide—a figure set to rise to 1.4 billion by 2030—menopause remains under-prioritized and under-resourced by ...
Bayer pharma chief sees no big acquisitions in near future
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...